1. Home
  2. EARN vs SAVA Comparison

EARN vs SAVA Comparison

Compare EARN & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.32

Market Cap

189.7M

Sector

Real Estate

ML Signal

HOLD

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.19

Market Cap

156.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
SAVA
Founded
2012
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
156.5M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
EARN
SAVA
Price
$5.32
$2.19
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$5.88
$5.00
AVG Volume (30 Days)
323.8K
1.2M
Earning Date
02-20-2026
11-12-2025
Dividend Yield
18.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
N/A
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$1.15
52 Week High
$6.86
$4.98

Technical Indicators

Market Signals
Indicator
EARN
SAVA
Relative Strength Index (RSI) 52.63 30.57
Support Level $5.10 $2.77
Resistance Level $5.20 $3.32
Average True Range (ATR) 0.10 0.21
MACD -0.00 -0.07
Stochastic Oscillator 60.18 6.61

Price Performance

Historical Comparison
EARN
SAVA

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: